[Ophthalmologic complications of low-dosage tamoxifen in the treatment of breast carcinoma].

Two out of 20 patients treated for metastatic or non-metastatic breast cancer with tamoxifen (20 mg 2 dd) developed bilateral secondary tapetoretinal degeneration. In one patient in whom the medication was stopped there was still slight progression of degeneration afterwards. In the other patient tamoxifen was continued under strict ophthalmological control. The total doses have been 7.3 g and 43.8 g respectively.